Healthcare

In its October 2026 presentation, Resonance Health reported FY26 revenue of $15.8 million, up 42% on FY25, normalised EBITDA of $2.6 million (a 16% margin) and statutory net profit after tax of $1.5 million. Operating cash inflow was $2.9 million, and net cash was …

In its 30 September 2026 announcement, Vectus said the US FDA granted its request for a pre-Investigational New Drug Type B meeting on its proposed development program for VB0004 in idiopathic pulmonary fibrosis. The FDA’s written responses are expected by mid-November 2026, and the …

Lumos Diagnostics shares traded at $0.067, down 20.24%, during the session. Lumos reported 265 US sites ordering FebriDx, Q1 FY27Revenueof US$2.0 million and cash of US$11.8 million, while its paediatric study enrolled below plan. The announcement is dated 27 October 2026.

Vectus Biosystems shares traded at $0.08, down 11.11%, during the session. Vectus Biosystems said the FDA granted a pre-IND meeting for VB0004 in idiopathic pulmonary fibrosis, with written responses expected by mid-November 2026.

Ansell Limited (ASX:ANN) shares touched a 52-week high during theTrading sessionon 26 October 2026, trading at $46.50, up 0.50% on the day. Ansell is a global provider of safety solutions. Its latest full-year results, released on 24 August 2026, cover the year ended 30 …

Doctor Care Anywhere Group PLC (ASX:DOC) CHESS Depositary Interests touched a 52-week low during theTrading sessionon 26 October 2026, trading at $0.10, down 9.09% on the day. Doctor Care Anywhere is a UK virtual healthcare provider delivering GP, mental health, physiotherapy and health assessment …

EVE Health Group Limited (ASX:EVE) shares touched a 52-week low during theTrading sessionon 26 October 2026, trading at $0.011, down 26.67% on the day. EVE is an Australian health company that develops and commercialises wellness and pharmaceutical products through its subsidiaries Meluka Australia and …